Sunday, September 21, 2008

Maxygen and Astellas Announce Global Agreement to Develop New Therapies for Autoimmune Diseases and Transplantation

Sep 19, 2008 - Maxygen, Inc. (Nasdaq:MAXY) and Astellas Pharma Inc. today announced a global agreement under which Astellas will receive worldwide rights to commercialize MAXY-4 lead candidates for all autoimmune diseases and transplant rejection.

The details can be read here.

No comments: